Full Press Release Details
Kitov Granted Notice of Allowance from U.S.
Patent & Trademark Office for KIT-302
Patent Further Strengthens Company's
IP position ahead of Planned New Drug Application to be Submitted to FDA
Tel Aviv, Israel -- February 1, 2017 -- Kitov Pharmaceuticals
Holdings Ltd. (NASDAQ: KTOV; TASE: KTOV), an innovative biopharmaceutical company, announced today that the U.S. Patent and Trademark
Office has issued a Notice of Allowance to the Company related to claims expanding the patent coverage for its lead drug candidate,
KIT-302, to include oral dosage compositions containing both amlodipine and celecoxib.
Notice of Allowance should result in the issuance of an additional patent, which is expected to further strengthen Kitov's
proprietary position and long-term U.S. market exclusivity for our lead compound, KIT-302, creating a higher barrier to entry for
potential competitors. We plan to continue to evaluate and grow
intellectual property rights of our amlodipine/celecoxib combination platform," stated Kitov CEO, Isaac Israel.
Mr. Israel further noted, "The preparation of our New Drug
Application (NDA) for KIT-302 to be submitted to the U.S. Food and Drug Administration is continuing and is expected to be completed
within the first quarter of 2017, as scheduled."
About the Additional Patent Allowance for KIT-302
In August 2016, Kitov Pharmaceuticals, Ltd., Kitov's wholly
owned subsidiary, was awarded U.S. Patent 9,408,837. That patent covers methods of ameliorating celecoxib-induced elevation
of blood pressure by providing a subject with celecoxib and amlodipine, where the amlodipine reduces blood pressure elevation
caused by the celecoxib. Kitov Pharmaceuticals, Ltd. has now obtained a Notice of Allowance on a continuation application
filed from the application which yielded Patent 9,408,837. The new patent, which is expected to issue from the continuation
application in the next few months, is expected to expand the sphere of protection over Kitov's amlodipine/celecoxib combination
therapy by having claims which cover oral dosage compositions containing both amlodipine and celecoxib. Examples of oral
dosage compositions include capsules, gelcaps, caplets, tablets, and liquids. These claims are expected to cover oral dosage
compositions containing both the combination of amlodipine and celecoxib alone or together with other compounds or ingredients.
About Kitov Pharmaceuticals
Kitov Pharmaceuticals (NASDAQ/TASE: KTOV) is an innovative biopharmaceutical
drug development company. Leveraging deep regulatory and clinical-trial expertise, Kitov's veteran team of healthcare and research
professionals maintains a proven track record in streamlined end-to-end drug development and approval. Kitov's flagship combination
drug, KIT-302, intended to treat osteoarthritis pain and hypertension simultaneously, achieved the primary efficacy endpoint for
its Phase III clinical trial. KIT-302's New Drug Application with the U.S. Food and Drug Administration is currently being
prepared for submission. Kitov's newest drug NT219, a potential immuno-oncology combination product, is being developed by Kitov's
recently acquired subsidiary, TyrNovo Ltd. NT219 is a small molecule that presents a new concept in cancer therapy. In combination
with various approved oncology drugs, NT219 demonstrated potent anti-tumor effects and increased survival in various cancer models,
including sarcoma, melanoma, pancreatic, lung, ovarian, head & neck, prostate and colon cancers. Its mechanism of action is
through the prevention of acquired resistance in tumors and by regression of resistant tumors. By lowering development risk and
cost, including via fast-track regulatory approval of novel late-stage and other therapeutics, Kitov plans to deliver rapid ROI
and long-term potential to investors, while making a meaningful impact on people's lives. For more information on Kitov, the content
of which is not part of this press release, please visit http://www.kitovpharma.com.
Forward-Looking Statements and Kitov's Safe Harbor Statement
Certain statements in this press release are forward-looking statements
within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other applicable securities
laws. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect",
"intend", "plan", "may", "should", "could", "might", "seek",
"target", "will", "project", "forecast", "continue" or "anticipate"
or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly
to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future
performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events,
and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties
and other factors that may cause our actual results, performance or achievements to be significantly different from any future
results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause
or contribute to such differences include, among others, risks relating to: the fact that drug development and commercialization
involves a lengthy and expensive process with uncertain outcomes; our ability to successfully acquire, develop or commercialize
our pharmaceutical products; the expense, length, progress and results of any clinical trials; the lack of sufficient funding to
finance the clinical trials; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry;
the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting
actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment
and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market
reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products;
patents attained by competitors; dependence on the effectiveness of our patents and other protections for innovative products;
our ability to obtain, maintain and defend issued patents with protective claims; the commencement of any patent interference or
infringement action; our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure
to litigation, including patent litigation, and/or regulatory actions, and other factors that are discussed in our Registration
Statements on Form F-3 filed with the U.S. Securities and Exchange Commission (the "SEC") (file numbers 333-211477, 333-207117,
and 333-215037), in our Annual Report on Form 20-F for the year ended December 31, 2015 and in our other filings with the SEC,
including our cautionary discussion of risks and uncertainties under "Risk Factors" in our Registration Statements and
Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected results. Other
factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks
only as of the date which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking
statement, or other information contained herein, whether as a result of new information, future events or otherwise, except as
required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC,
which are available on the SEC's website, http://www.sec.gov.
Chief Financial Officer
+972-3-9333121 ext. #105
LifeSci Advisors, LLC